Skip to main content
Premium Trial:

Request an Annual Quote

Gene Expression Startup Genometry Raises $3M

NEW YORK (GenomeWeb News) – Gene expression company Genometry has raised $3 million in a Series A equity round of funding.

Genometry President and CEO Justin Lamb said that the funds will go toward establishing its operations and running the business. According to the company's Form D filed with the US Securities and Exchange Commission, the round had 11 investors. Lamb declined to identify the investors in the round but said they comprise venture firms, private equity firms, and a corporate strategic investor.

On its website, Cambridge, Mass.-based Genometry calls itself a platform technology firm that was founded to commercialize a genome-wide, high-throughput, low-cost gene expression profiling method called L1000 for pharmaceutical applications. It exclusively licensed patents covering the technology from the Broad Institute, MIT, and the Dana-Farber Cancer Institute.

L1000, the firm said, produces high-dimensional, gene expression profiles "from crude cell lysates in [a] 384 well plate format at a rate of thousands a day and at only a fraction of the cost of conventional microarray-based methods."

The company offers data generation and primary analysis solutions, and in partnership with drug manufacturers is "pioneering" a digital open innovation platform, it added.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.